JP2013520442A - 卵巣癌の治療のための抗血管新生治療 - Google Patents

卵巣癌の治療のための抗血管新生治療 Download PDF

Info

Publication number
JP2013520442A
JP2013520442A JP2012554084A JP2012554084A JP2013520442A JP 2013520442 A JP2013520442 A JP 2013520442A JP 2012554084 A JP2012554084 A JP 2012554084A JP 2012554084 A JP2012554084 A JP 2012554084A JP 2013520442 A JP2013520442 A JP 2013520442A
Authority
JP
Japan
Prior art keywords
vegf
antibody
treatment
cancer
chemotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012554084A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013520442A5 (OSRAM
Inventor
ジェイコブ デュポン，
コルネリア アール，
Original Assignee
ジェネンテック， インコーポレイテッド
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44476669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013520442(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ジェネンテック， インコーポレイテッド, エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2013520442A publication Critical patent/JP2013520442A/ja
Publication of JP2013520442A5 publication Critical patent/JP2013520442A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00—Subject matter not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • General Business, Economics & Management (AREA)
  • Business, Economics & Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012554084A 2010-02-23 2011-02-22 卵巣癌の治療のための抗血管新生治療 Withdrawn JP2013520442A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US30709510P 2010-02-23 2010-02-23
US61/307,095 2010-02-23
US35123110P 2010-06-03 2010-06-03
US61/351,231 2010-06-03
US36005910P 2010-06-30 2010-06-30
US61/360,059 2010-06-30
US201161439819P 2011-02-04 2011-02-04
US61/439,819 2011-02-04
PCT/US2011/025651 WO2011106300A2 (en) 2010-02-23 2011-02-22 Anti-angiogenesis therapy for the treatment of ovarian cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013094727A Division JP6184733B2 (ja) 2010-02-23 2013-04-26 卵巣癌の治療のための抗血管新生治療

Publications (2)

Publication Number Publication Date
JP2013520442A true JP2013520442A (ja) 2013-06-06
JP2013520442A5 JP2013520442A5 (OSRAM) 2013-09-26

Family

ID=44476669

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2012554084A Withdrawn JP2013520442A (ja) 2010-02-23 2011-02-22 卵巣癌の治療のための抗血管新生治療
JP2013094727A Active JP6184733B2 (ja) 2010-02-23 2013-04-26 卵巣癌の治療のための抗血管新生治療
JP2015153726A Withdrawn JP2016020354A (ja) 2010-02-23 2015-08-03 卵巣癌の治療のための抗血管新生治療
JP2017094206A Pending JP2017193551A (ja) 2010-02-23 2017-05-10 卵巣癌の治療のための抗血管新生治療
JP2018142978A Withdrawn JP2018199683A (ja) 2010-02-23 2018-07-30 卵巣癌の治療のための抗血管新生治療
JP2020126490A Pending JP2020196719A (ja) 2010-02-23 2020-07-27 卵巣癌の治療のための抗血管新生治療

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2013094727A Active JP6184733B2 (ja) 2010-02-23 2013-04-26 卵巣癌の治療のための抗血管新生治療
JP2015153726A Withdrawn JP2016020354A (ja) 2010-02-23 2015-08-03 卵巣癌の治療のための抗血管新生治療
JP2017094206A Pending JP2017193551A (ja) 2010-02-23 2017-05-10 卵巣癌の治療のための抗血管新生治療
JP2018142978A Withdrawn JP2018199683A (ja) 2010-02-23 2018-07-30 卵巣癌の治療のための抗血管新生治療
JP2020126490A Pending JP2020196719A (ja) 2010-02-23 2020-07-27 卵巣癌の治療のための抗血管新生治療

Country Status (20)

Country Link
US (8) US8778340B2 (OSRAM)
EP (3) EP3064509A3 (OSRAM)
JP (6) JP2013520442A (OSRAM)
KR (4) KR102104197B1 (OSRAM)
CN (3) CN110227154A (OSRAM)
AR (1) AR080244A1 (OSRAM)
AU (5) AU2011221229B2 (OSRAM)
BR (1) BR112012020700A8 (OSRAM)
CA (2) CA2930248A1 (OSRAM)
CL (1) CL2012002326A1 (OSRAM)
CO (1) CO6592072A2 (OSRAM)
IL (2) IL221058B (OSRAM)
MA (1) MA34059B1 (OSRAM)
MX (3) MX2012009554A (OSRAM)
PH (2) PH12012501681A1 (OSRAM)
RU (1) RU2012140447A (OSRAM)
SG (2) SG10201401123VA (OSRAM)
TW (2) TWI457135B (OSRAM)
UA (1) UA114277C2 (OSRAM)
WO (1) WO2011106300A2 (OSRAM)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015525798A (ja) * 2012-08-07 2015-09-07 ジェネンテック， インコーポレイテッド 神経膠芽腫の治療のための併用療法
JP2017514854A (ja) * 2014-05-07 2017-06-08 メディミューン，エルエルシー 抗ａｎｇ２抗体を用いる方法
JP2018527383A (ja) * 2015-09-17 2018-09-20 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ
US10208355B2 (en) 2014-07-14 2019-02-19 Genentech, Inc. Method of treatment for glioblastoma by administering a VEGF antagonist
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
DK3485903T5 (da) 2011-09-23 2024-09-02 Mereo Biopharma 5 Inc Vegf/dll4-bindende midler og anvendelser deraf
MX365139B (es) * 2012-03-13 2019-05-24 Hoffmann La Roche Uso de una terapia combinada de bevacizumab y paclitaxel en el tratamiento de cáncer de ovario epitelial resistente al platino, carcinoma de las trompas de falopio resistente al platino, o carcinoma peritoneal primario resistente al platino.
MX361337B (es) 2012-07-13 2018-12-04 Roche Glycart Ag Anticuerpos biespecificos anti-factor de crecimiento endotelial vascular humano (vegf) / anti-angiopoyetina-2 humana (ang-2) y su uso en el tratamiento de enfermedades vasculares oculares.
SI3105246T1 (sl) 2014-02-10 2021-11-30 Merck Patent Gmbh Ciljana inhibicija TGF BETA
DK3127545T3 (da) * 2014-04-04 2020-08-10 Taiho Pharmaceutical Co Ltd Antitumorlægemiddel, der indeholder taxanforbindelse, og anti- tumorvirkningsfremmer
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
RU2017120388A (ru) * 2014-11-14 2018-12-14 Дженентек, Инк. Прогнозирование ответа на антагонист vegf
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
TW201713360A (en) * 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
EP3272771A1 (en) * 2016-07-22 2018-01-24 Centre National De La Recherche Scientifique Treatment for use for preventing metastasis in a subject exposed to cancer treatment inducing p38 activation
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
US20220064274A1 (en) * 2018-03-26 2022-03-03 Shanghai Yile Biotechnology Co., Ltd. Use of probdnf regulator in b cell-related diseases
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
BR112023018305A2 (pt) * 2021-03-10 2023-10-31 Canariabio Inc Uso de oregovomabe e bevacizumabe, paclitaxel, carboplatina para tratamento de recidiva de brca do tipo selvagem sensível à platina
CN120695174A (zh) * 2021-07-01 2025-09-26 江苏先声生物制药有限公司 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
WO2023196153A1 (en) * 2022-04-04 2023-10-12 Merck Sharp & Dohme Llc Methods for treating cancer, an infectious disease or an infection using a combination of a tigit antagonist, a pd-1 antagonist, and a vegf antagonist

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057562A1 (en) * 2006-11-06 2008-05-15 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US991302A (en) * 1910-03-28 1911-05-02 Frederick G Hepburn Waste-supporter.
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE348110T1 (de) 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
SI1516628T1 (sl) 1995-07-27 2013-10-30 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
SI1695985T1 (sl) 1997-04-07 2011-06-30 Genentech Inc Postopki za tvorbo humaniziranih protiteles z naključno mutagenezo
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
PT1068241E (pt) 1998-04-02 2007-11-19 Genentech Inc Variantes de anticorpos e respectivos fragmentos
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US20030175884A1 (en) 2001-08-03 2003-09-18 Pablo Umana Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
JP2003518075A (ja) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
RS20050885A (sr) * 2003-05-30 2008-04-04 Genentech Lečenje sa anti-vegf antitelima
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
GT200500155A (es) * 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
EP1784426B1 (en) * 2004-09-03 2011-11-23 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
PE20091434A1 (es) * 2007-10-30 2009-10-17 Genentech Inc Purificacion de anticuerpos por cromatografia de intercambio cationico
KR20170015525A (ko) 2008-11-22 2017-02-08 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057562A1 (en) * 2006-11-06 2008-05-15 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
JPN6013023792; Ｊ．　Ｃｌｉｎ．　Ｏｎｃｏｌ． Ｖｏｌ．２８，　Ｎｏ．１, 20100101, ｐ．１５４-１５９ *
JPN6013023794; Ｊ．　Ｃｌｉｎ．　Ｏｎｃｏｌ． Ｖｏｌ．２７，　Ｎｏ．１５ｓ, 2009, Ａｂｓｔｒａｃｔ　Ｎｏ．５５４０ *
JPN6013023795; Ｊ．　Ｃｌｉｎ．　Ｏｎｃｏｌ． Ｖｏｌ．２５，　Ｎｏ．１８ｓ, 2007, Ａｂｓｔｒａｃｔ　Ｎｏ．５５１８ *
JPN6013023797; Ｊ．　Ｃｌｉｎ．　Ｏｎｃｏｌ． Ｖｏｌ．２７，　Ｎｏ．１５ｓ, 2009, Ａｂｓｔｒａｃｔ　Ｎｏ．５５４６ *
JPN6013023798; Ｇｙｎｅｃｏｌ．　Ｏｎｃｏｌ． Ｖｏｌ．１１２，　Ｎｏ．２, 2009, ｐ．Ｓ２７，　Ａｂｓｔｒａｃｔ　Ｎｏ．４８ *
JPN6013023800; Ｅｘｐ．　Ｒｅｖ．　Ａｎｔｉｃａｎｃｅｒ　Ｔｈｅｒ． Ｖｏｌ．７，　Ｎｏ．１０, 2007, ｐ．１３３９-４５ *
JPN6013023802; Ｇｙｎｅｃｏｌ．　Ｏｎｃｏｌ． Ｖｏｌ．１１５，　Ｎｏ．２, 2009, ｐ．２９０-３０１ *
JPN6013023803; 癌と化学療法 Ｖｏｌ．３６，　Ｎｏ．５, 2009, ｐ．７３０-７３５ *
JPN6013023805; Ｃｌｉｎ．　Ｃａｎｃｅｒ　Ｒｅｓ． Ｖｏｌ．１４，　Ｎｏ．２３, 2008, ｐ．７７８１-７７８９ *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015525798A (ja) * 2012-08-07 2015-09-07 ジェネンテック， インコーポレイテッド 神経膠芽腫の治療のための併用療法
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
JP2017514854A (ja) * 2014-05-07 2017-06-08 メディミューン，エルエルシー 抗ａｎｇ２抗体を用いる方法
US10208355B2 (en) 2014-07-14 2019-02-19 Genentech, Inc. Method of treatment for glioblastoma by administering a VEGF antagonist
JP2018527383A (ja) * 2015-09-17 2018-09-20 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ
JP2021107452A (ja) * 2015-09-17 2021-07-29 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ
JP2023101813A (ja) * 2015-09-17 2023-07-21 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ
JP7703593B2 (ja) 2015-09-17 2025-07-07 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ

Also Published As

Publication number Publication date
US20140178371A1 (en) 2014-06-26
TWI619509B (zh) 2018-04-01
US20230226179A1 (en) 2023-07-20
CO6592072A2 (es) 2013-01-02
IL258612A (en) 2018-06-28
US20110206662A1 (en) 2011-08-25
EP3064509A3 (en) 2016-11-02
MX2019000425A (es) 2023-04-27
AU2011221229B2 (en) 2015-06-18
SG183414A1 (en) 2012-09-27
IL258612B (en) 2022-01-01
JP2017193551A (ja) 2017-10-26
AU2011221229A1 (en) 2012-08-16
UA114277C2 (uk) 2017-05-25
MX2012009554A (es) 2012-11-23
MA34059B1 (fr) 2013-03-05
AU2019210484A1 (en) 2019-08-15
AU2019203466A1 (en) 2019-06-06
BR112012020700A8 (pt) 2018-01-02
TW201138819A (en) 2011-11-16
KR101839161B9 (ko) 2022-10-18
US20160279241A1 (en) 2016-09-29
TWI457135B (zh) 2014-10-21
PH12012501681A1 (en) 2012-11-05
AU2017204320B2 (en) 2019-02-21
BR112012020700A2 (pt) 2017-03-21
US20180344847A1 (en) 2018-12-06
CA2787952C (en) 2016-07-26
TW201526912A (zh) 2015-07-16
US20170143826A1 (en) 2017-05-25
JP2016020354A (ja) 2016-02-04
KR101839161B1 (ko) 2018-03-16
AR080244A1 (es) 2012-03-21
JP6184733B2 (ja) 2017-08-23
WO2011106300A2 (en) 2011-09-01
EP2539367A2 (en) 2013-01-02
KR20180135101A (ko) 2018-12-19
KR20130010884A (ko) 2013-01-29
KR20180028561A (ko) 2018-03-16
JP2020196719A (ja) 2020-12-10
CN110227154A (zh) 2019-09-13
EP3696194A1 (en) 2020-08-19
CL2012002326A1 (es) 2012-11-30
CN120733043A (zh) 2025-10-03
KR20190143480A (ko) 2019-12-30
US8778340B2 (en) 2014-07-15
US20210052728A1 (en) 2021-02-25
AU2015210479A1 (en) 2015-09-03
KR102104197B1 (ko) 2020-04-24
EP3064509A2 (en) 2016-09-07
WO2011106300A3 (en) 2011-12-15
AU2017204320A1 (en) 2017-07-13
JP2018199683A (ja) 2018-12-20
JP2013173775A (ja) 2013-09-05
KR102104197B9 (ko) 2022-10-21
RU2012140447A (ru) 2014-03-27
CA2787952A1 (en) 2011-09-01
CA2930248A1 (en) 2011-09-01
SG10201401123VA (en) 2014-08-28
CN103237810A (zh) 2013-08-07
US20250177522A1 (en) 2025-06-05
IL221058B (en) 2018-04-30
MX369170B (es) 2019-10-30
PH12016501728A1 (en) 2018-02-12

Similar Documents

Publication Publication Date Title
US20250177522A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
JP2012524083A (ja) アジュバント癌治療
JP2016117718A (ja) 以前に治療された乳癌の治療のための抗血管新生療法
HK40013836A (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
HK1183046A (en) Anti-angiogenesis therapy for the treatment of ovarian cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130425

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20130425

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20130514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130521

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131206

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140213

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141222

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20151110